T9	B-Entity	0	3	TAR	TAR	B-NP	NN	B-DNA	4	NMOD	B-DNA
O	O	3	4	-	-	I-NP	HYPH	O	4	P	O
O	O	4	15	independent	independent	I-NP	JJ	O	4	NMOD	O
O	O	16	31	transactivation	transactivation	I-NP	NN	O	16	NMOD	O
O	O	32	34	by	by	B-PP	IN	O	4	NMOD	O
T1	B-Protein	35	38	Tat	Tat	B-NP	NN	B-protein	5	PMOD	B-protein
O	O	39	41	in	in	B-PP	IN	O	4	NMOD	O
O	O	42	47	cells	cell	B-NP	NNS	O	7	PMOD	O
O	O	48	55	derived	derive	B-VP	VBN	O	8	NMOD	O
O	O	56	60	from	from	B-PP	IN	O	9	VMOD	O
O	O	61	64	the	the	B-NP	DT	O	12	NMOD	O
O	O	65	68	CNS	CNS	I-NP	NN	B-protein	10	PMOD	B-protein
O	O	68	69	:	:	O	:	O	4	P	O
O	O	70	71	a	a	B-NP	DT	O	16	NMOD	O
O	O	72	77	novel	novel	I-NP	JJ	O	16	NMOD	O
O	O	78	87	mechanism	mechanism	I-NP	NN	O	0	ROOT	O
O	O	88	90	of	of	B-PP	IN	O	16	NMOD	O
T10	B-Entity	91	94	HIV	HIV	B-NP	NN	B-DNA	21	NMOD	B-DNA
T10	I-Entity	94	95	-	-	B-NP	HYPH	I-DNA	21	NMOD	I-DNA
T10	I-Entity	95	96	1	1	I-NP	CD	I-DNA	21	NMOD	I-DNA
T10	I-Entity	97	101	gene	gene	I-NP	NN	I-DNA	22	NMOD	I-DNA
O	O	102	112	regulation	regulation	I-NP	NN	O	17	PMOD	O
O	O	112	113	.	.	O	.	O	16	P	O

O	O	115	118	The	The	B-NP	DT	O	3	NMOD	O
T2	B-Protein	119	122	Tat	Tat	I-NP	NN	B-protein	3	NMOD	B-protein
O	O	123	130	protein	protein	I-NP	NN	I-protein	15	SUB	I-protein
O	O	131	133	of	of	B-PP	IN	O	3	NMOD	O
O	O	134	139	human	human	B-NP	JJ	O	8	NMOD	O
O	O	140	156	immunodeficiency	immunodeficiency	I-NP	NN	O	8	NMOD	O
O	O	157	162	virus	virus	I-NP	NN	O	8	NMOD	O
O	O	163	167	type	type	I-NP	NN	O	4	PMOD	O
O	O	168	169	1	1	I-NP	CD	O	8	NMOD	O
O	O	170	171	(	(	O	(	O	14	DEP	O
O	O	171	174	HIV	HIV	B-NP	NN	O	13	NMOD	O
O	O	174	175	-	-	B-NP	HYPH	O	13	P	O
O	O	175	176	1	1	I-NP	CD	O	14	DEP	O
O	O	176	177	)	)	O	)	O	8	NMOD	O
O	O	178	180	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	181	190	essential	essential	B-ADJP	JJ	O	15	PRD	O
O	O	191	194	for	for	B-PP	IN	O	16	AMOD	O
O	O	195	205	productive	productive	B-NP	JJ	O	19	NMOD	O
O	O	206	215	infection	infection	I-NP	NN	O	17	PMOD	O
O	O	216	219	and	and	O	CC	O	15	VMOD	O
O	O	220	222	is	be	B-VP	VBZ	O	15	VMOD	O
O	O	223	224	a	a	B-NP	DT	O	24	NMOD	O
O	O	225	234	potential	potential	I-NP	JJ	O	24	NMOD	O
O	O	235	241	target	target	I-NP	NN	O	21	PRD	O
O	O	242	245	for	for	B-PP	IN	O	24	NMOD	O
O	O	246	255	antiviral	antiviral	B-NP	JJ	O	27	NMOD	O
O	O	256	263	therapy	therapy	I-NP	NN	O	25	PMOD	O
O	O	263	264	.	.	O	.	O	15	P	O

T3	B-Protein	265	268	Tat	Tat	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	268	269	,	,	O	,	O	5	P	O
O	O	270	271	a	a	B-NP	DT	O	5	NMOD	O
O	O	272	278	potent	potent	I-NP	JJ	O	5	NMOD	O
O	O	279	288	activator	activator	I-NP	NN	O	13	SUB	O
O	O	289	291	of	of	B-PP	IN	O	5	NMOD	O
O	O	292	295	HIV	HIV	B-NP	NN	O	11	NMOD	O
O	O	295	296	-	-	B-NP	HYPH	O	11	NMOD	O
O	O	296	297	1	1	I-NP	CD	O	11	NMOD	O
O	O	298	302	gene	gene	I-NP	NN	O	11	NMOD	O
O	O	303	313	expression	expression	I-NP	NN	O	6	PMOD	O
O	O	313	314	,	,	O	,	O	5	P	O
O	O	315	321	serves	serve	B-VP	VBZ	O	0	ROOT	O
O	O	322	324	to	to	I-VP	TO	O	16	VMOD	O
O	O	325	332	greatly	greatly	I-VP	RB	O	16	VMOD	O
O	O	333	341	increase	increase	I-VP	VB	O	13	VMOD	O
O	O	342	345	the	the	B-NP	DT	O	18	NMOD	O
O	O	346	350	rate	rate	I-NP	NN	O	16	OBJ	O
O	O	351	353	of	of	B-PP	IN	O	18	NMOD	O
O	O	354	367	transcription	transcription	B-NP	NN	O	19	PMOD	O
O	O	368	376	directed	direct	B-VP	VBN	O	20	NMOD	O
O	O	377	379	by	by	B-PP	IN	O	21	VMOD	O
O	O	380	383	the	the	B-NP	DT	O	25	NMOD	O
T11	B-Entity	384	389	viral	viral	I-NP	JJ	B-DNA	25	NMOD	B-DNA
T11	I-Entity	390	398	promoter	promoter	I-NP	NN	I-DNA	22	PMOD	I-DNA
O	O	398	399	.	.	O	.	O	13	P	O

O	O	400	404	This	This	B-NP	DT	O	2	NMOD	O
O	O	405	414	induction	induction	I-NP	NN	O	23	SUB	O
O	O	414	415	,	,	O	,	O	2	P	O
O	O	416	421	which	which	B-NP	WDT	O	2	NMOD	O
O	O	422	427	seems	seem	B-VP	VBZ	O	4	SBAR	O
O	O	428	430	to	to	I-VP	TO	O	7	VMOD	O
O	O	431	433	be	be	I-VP	VB	O	5	VMOD	O
O	O	434	436	an	an	B-NP	DT	O	10	NMOD	O
O	O	437	446	important	important	I-NP	JJ	O	10	NMOD	O
O	O	447	456	component	component	I-NP	NN	O	7	PRD	O
O	O	457	459	in	in	B-PP	IN	O	10	NMOD	O
O	O	460	463	the	the	B-NP	DT	O	13	NMOD	O
O	O	464	475	progression	progression	I-NP	NN	O	11	PMOD	O
O	O	476	478	of	of	B-PP	IN	O	13	NMOD	O
O	O	479	487	acquired	acquire	B-NP	VBN	O	18	NMOD	O
O	O	488	494	immune	immune	I-NP	JJ	O	18	NMOD	O
O	O	495	505	deficiency	deficiency	I-NP	NN	O	18	NMOD	O
O	O	506	514	syndrome	syndrome	I-NP	NN	O	14	PMOD	O
O	O	515	516	(	(	O	(	O	21	DEP	O
O	O	516	520	AIDS	AIDS	B-NP	NN	O	21	DEP	O
O	O	520	521	)	)	O	)	O	18	NMOD	O
O	O	521	522	,	,	O	,	O	2	P	O
O	O	523	526	may	may	B-VP	MD	O	0	ROOT	O
O	O	527	529	be	be	I-VP	VB	O	23	VC	O
O	O	530	533	due	due	B-PP	JJ	O	26	PMOD	O
O	O	534	536	to	to	B-PP	TO	O	24	PRD	O
O	O	537	546	increased	increase	B-NP	VBN	O	29	NMOD	O
O	O	547	562	transcriptional	transcriptional	I-NP	JJ	O	29	NMOD	O
O	O	563	573	initiation	initiation	I-NP	NN	O	37	NMOD	O
O	O	573	574	,	,	O	,	O	37	P	O
O	O	575	584	increased	increase	B-NP	VBN	O	33	NMOD	O
O	O	585	600	transcriptional	transcriptional	I-NP	JJ	O	33	NMOD	O
O	O	601	611	elongation	elongation	I-NP	NN	O	37	NMOD	O
O	O	611	612	,	,	O	,	O	37	P	O
O	O	613	615	or	or	O	CC	O	37	NMOD	O
O	O	616	617	a	a	B-NP	DT	O	37	NMOD	O
O	O	618	629	combination	combination	I-NP	NN	O	26	PMOD	O
O	O	630	632	of	of	B-PP	IN	O	37	NMOD	O
O	O	633	638	these	these	B-NP	DT	O	40	NMOD	O
O	O	639	648	processes	process	I-NP	NNS	O	38	PMOD	O
O	O	648	649	.	.	O	.	O	23	P	O

O	O	650	654	Much	Much	B-NP	JJ	O	2	NMOD	O
O	O	655	664	attention	attention	I-NP	NN	O	3	SUB	O
O	O	665	668	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	669	673	been	be	I-VP	VBN	O	3	VC	O
O	O	674	681	focused	focus	I-VP	VBN	O	4	VC	O
O	O	682	684	on	on	B-PP	IN	O	5	VMOD	O
O	O	685	688	the	the	B-NP	DT	O	8	NMOD	O
O	O	689	700	interaction	interaction	I-NP	NN	O	6	PMOD	O
O	O	701	703	of	of	B-PP	IN	O	8	NMOD	O
T4	B-Protein	704	707	Tat	Tat	B-NP	NN	B-protein	9	PMOD	B-protein
O	O	708	712	with	with	B-PP	IN	O	8	NMOD	O
O	O	713	714	a	a	B-NP	DT	O	15	NMOD	O
O	O	715	723	specific	specific	I-NP	JJ	O	15	NMOD	O
T12	B-Entity	724	727	RNA	RNA	I-NP	NN	B-RNA	15	NMOD	B-RNA
T12	I-Entity	728	734	target	target	I-NP	NN	I-RNA	11	PMOD	I-RNA
O	O	735	741	termed	term	B-VP	VBN	O	15	NMOD	O
T13	B-Entity	742	745	TAR	TAR	B-NP	NN	B-DNA	16	VMOD	B-DNA
O	O	746	747	(	(	O	(	O	21	DEP	O
T14	B-Entity	747	762	transactivation	transactivation	B-NP	NN	O	20	NMOD	O
T14	I-Entity	763	773	responsive	responsive	B-ADJP	JJ	O	21	DEP	O
O	O	773	774	)	)	O	)	O	17	NMOD	O
O	O	775	780	which	which	B-NP	WDT	O	15	NMOD	O
O	O	781	783	is	be	B-VP	VBZ	O	22	SBAR	O
O	O	784	791	present	present	B-ADJP	JJ	O	23	PRD	O
O	O	792	794	in	in	B-PP	IN	O	24	AMOD	O
O	O	795	798	the	the	B-NP	DT	O	28	NMOD	O
O	O	799	805	leader	leader	I-NP	NN	B-DNA	28	NMOD	B-DNA
O	O	806	814	sequence	sequence	I-NP	NN	I-DNA	25	PMOD	I-DNA
O	O	815	817	of	of	B-PP	IN	O	28	NMOD	O
O	O	818	821	all	all	B-NP	DT	O	31	NMOD	O
O	O	822	825	HIV	HIV	I-NP	NN	B-RNA	34	NMOD	B-RNA
O	O	825	826	-	-	B-NP	HYPH	I-RNA	34	NMOD	I-RNA
O	O	826	827	1	1	I-NP	CD	I-RNA	34	NMOD	I-RNA
O	O	828	833	mRNAs	mRNA	I-NP	NNS	I-RNA	29	PMOD	I-RNA
O	O	833	834	.	.	O	.	O	3	P	O

O	O	835	839	This	This	B-NP	DT	O	2	NMOD	O
O	O	840	851	interaction	interaction	I-NP	NN	O	3	SUB	O
O	O	852	854	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	855	863	believed	believe	I-VP	VBN	O	3	VC	O
O	O	864	866	to	to	I-VP	TO	O	6	VMOD	O
O	O	867	869	be	be	I-VP	VB	O	4	VMOD	O
O	O	870	872	an	an	B-NP	DT	O	9	NMOD	O
O	O	873	882	important	important	I-NP	JJ	O	9	NMOD	O
O	O	883	892	component	component	I-NP	NN	O	6	PRD	O
O	O	893	895	of	of	B-PP	IN	O	9	NMOD	O
O	O	896	899	the	the	B-NP	DT	O	12	NMOD	O
O	O	900	909	mechanism	mechanism	I-NP	NN	O	10	PMOD	O
O	O	910	912	of	of	B-PP	IN	O	12	NMOD	O
O	O	913	928	transactivation	transactivation	B-NP	NN	O	13	PMOD	O
O	O	928	929	.	.	O	.	O	3	P	O

O	O	930	932	In	In	B-PP	IN	O	5	VMOD	O
O	O	933	937	this	this	B-NP	DT	O	3	NMOD	O
O	O	938	944	report	report	I-NP	NN	O	1	PMOD	O
O	O	945	947	we	we	B-NP	PRP	O	5	SUB	O
O	O	948	959	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	960	964	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	965	967	in	in	B-PP	IN	O	14	VMOD	O
O	O	968	975	certain	certain	B-NP	JJ	O	12	NMOD	O
O	O	976	979	CNS	CNS	I-NP	NN	B-protein	8	NMOD	B-protein
O	O	979	980	-	-	B-NP	HYPH	O	12	P	O
O	O	980	987	derived	derive	I-NP	VBN	O	12	NMOD	O
O	O	988	993	cells	cell	I-NP	NNS	O	7	PMOD	O
T5	B-Protein	994	997	Tat	Tat	I-NP	NN	B-protein	14	SUB	B-protein
O	O	998	1000	is	be	B-VP	VBZ	O	6	SBAR	O
O	O	1001	1008	capable	capable	B-ADJP	JJ	O	14	PRD	O
O	O	1009	1011	of	of	B-PP	IN	O	15	AMOD	O
O	O	1012	1022	activating	activate	B-VP	VBG	O	16	PMOD	O
O	O	1023	1026	HIV	HIV	B-NP	NN	O	20	NMOD	O
O	O	1026	1027	-	-	B-NP	HYPH	O	20	P	O
O	O	1027	1028	1	1	I-NP	CD	O	17	OBJ	O
O	O	1029	1036	through	through	B-PP	IN	O	17	VMOD	O
O	O	1037	1038	a	a	B-NP	DT	O	23	NMOD	O
T15	B-Entity	1039	1042	TAR	TAR	I-NP	NN	B-DNA	21	PMOD	B-DNA
O	O	1042	1043	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	1043	1054	independent	independent	I-NP	JJ	O	26	NMOD	O
O	O	1055	1062	pathway	pathway	I-NP	NN	O	23	NMOD	O
O	O	1062	1063	.	.	O	.	O	5	P	O

O	O	1064	1065	A	A	B-NP	DT	O	5	NMOD	O
T6	B-Protein	1066	1069	Tat	Tat	I-NP	NN	B-DNA	5	NMOD	B-DNA
T16	B-Entity	1069	1070	-	-	B-NP	HYPH	I-DNA	5	NMOD	I-DNA
T16	I-Entity	1070	1080	responsive	responsive	I-NP	JJ	I-DNA	5	NMOD	I-DNA
T16	I-Entity	1081	1088	element	element	I-NP	NN	I-DNA	6	SUB	I-DNA
O	O	1089	1091	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	1092	1097	found	find	I-VP	VBN	O	6	VC	O
O	O	1098	1106	upstream	upstream	B-ADVP	RB	O	7	VMOD	O
O	O	1107	1113	within	within	B-PP	IN	O	7	VMOD	O
O	O	1114	1117	the	the	B-NP	DT	O	12	NMOD	O
T17	B-Entity	1118	1123	viral	viral	I-NP	JJ	B-DNA	12	NMOD	B-DNA
T17	I-Entity	1124	1132	promoter	promoter	I-NP	NN	I-DNA	9	PMOD	I-DNA
O	O	1133	1137	that	that	B-NP	IN	O	12	NMOD	O
O	O	1138	1140	in	in	B-PP	IN	O	20	VMOD	O
O	O	1141	1146	glial	glial	B-NP	JJ	B-cell_line	19	NMOD	B-cell_line
O	O	1146	1147	-	-	I-NP	HYPH	I-cell_line	19	NMOD	I-cell_line
O	O	1147	1154	derived	derive	I-NP	VBN	I-cell_line	19	NMOD	I-cell_line
O	O	1155	1159	cell	cell	I-NP	NN	I-cell_line	19	NMOD	I-cell_line
O	O	1160	1165	lines	line	I-NP	NNS	I-cell_line	14	PMOD	I-cell_line
O	O	1166	1172	allows	allow	B-VP	VBZ	O	13	SBAR	O
O	O	1173	1188	transactivation	transactivation	B-NP	NN	O	20	OBJ	O
O	O	1189	1191	in	in	B-PP	IN	O	20	VMOD	O
O	O	1192	1195	the	the	B-NP	DT	O	24	NMOD	O
O	O	1196	1203	absence	absence	I-NP	NN	O	22	PMOD	O
O	O	1204	1206	of	of	B-PP	IN	O	24	NMOD	O
T18	B-Entity	1207	1210	TAR	TAR	B-NP	NN	B-DNA	25	PMOD	B-DNA
O	O	1210	1211	.	.	O	.	O	6	P	O

O	O	1212	1220	Deletion	Deletion	B-NP	NN	O	2	NMOD	O
O	O	1221	1228	mapping	mapping	I-NP	NN	O	6	NMOD	O
O	O	1229	1232	and	and	I-NP	CC	O	6	NMOD	O
T19	B-Entity	1233	1239	hybrid	hybrid	I-NP	NN	B-DNA	6	NMOD	B-DNA
T19	I-Entity	1240	1248	promoter	promoter	I-NP	NN	I-DNA	6	NMOD	I-DNA
T19	I-Entity	1249	1259	constructs	construct	I-NP	NNS	I-DNA	7	SUB	I-DNA
O	O	1260	1271	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	1272	1276	that	that	B-SBAR	IN	O	7	VMOD	O
O	O	1277	1280	the	the	B-NP	DT	O	15	NMOD	O
O	O	1281	1286	newly	newly	I-NP	RB	O	11	AMOD	O
O	O	1287	1297	identified	identify	I-NP	VBN	O	15	NMOD	O
T7	B-Protein	1298	1301	Tat	Tat	I-NP	NN	B-DNA	15	NMOD	B-DNA
T20	B-Entity	1301	1302	-	-	I-NP	HYPH	I-DNA	15	NMOD	I-DNA
T20	I-Entity	1302	1312	responsive	responsive	I-NP	JJ	I-DNA	15	NMOD	I-DNA
T20	I-Entity	1313	1320	element	element	I-NP	NN	I-DNA	16	SUB	I-DNA
O	O	1321	1332	corresponds	correspond	B-VP	VBZ	O	8	SBAR	O
O	O	1333	1335	to	to	B-PP	TO	O	16	VMOD	O
O	O	1336	1337	a	a	B-NP	DT	O	19	NMOD	O
O	O	1338	1346	sequence	sequence	I-NP	NN	O	17	PMOD	O
O	O	1347	1353	within	within	B-PP	IN	O	19	NMOD	O
O	O	1354	1357	the	the	B-NP	DT	O	25	NMOD	O
T21	B-Entity	1358	1363	viral	viral	I-NP	JJ	B-DNA	25	NMOD	B-DNA
T21	I-Entity	1364	1368	long	long	I-NP	JJ	I-DNA	25	NMOD	I-DNA
T21	I-Entity	1369	1377	terminal	terminal	I-NP	JJ	I-DNA	25	NMOD	I-DNA
T21	I-Entity	1378	1384	repeat	repeat	I-NP	NN	I-DNA	20	PMOD	I-DNA
O	O	1385	1386	(	(	O	(	O	28	DEP	O
T22	B-Entity	1386	1389	LTR	LTR	B-NP	NN	B-DNA	28	DEP	B-DNA
O	O	1389	1390	)	)	O	)	O	25	NMOD	O
O	O	1391	1401	previously	previously	B-VP	RB	O	30	VMOD	O
O	O	1402	1412	identified	identify	I-VP	VBN	O	19	NMOD	O
O	O	1413	1415	as	as	B-PP	IN	O	30	VMOD	O
O	O	1416	1419	the	the	B-NP	DT	O	36	NMOD	O
T23	B-Entity	1420	1423	HIV	HIV	I-NP	NN	B-DNA	36	NMOD	B-DNA
T23	I-Entity	1423	1424	-	-	B-NP	HYPH	I-DNA	36	NMOD	I-DNA
T23	I-Entity	1424	1425	1	1	I-NP	CD	I-DNA	36	NMOD	I-DNA
T23	I-Entity	1426	1434	enhancer	enhancer	I-NP	NN	I-DNA	43	NMOD	I-DNA
O	O	1434	1435	,	,	O	,	O	43	P	O
O	O	1436	1438	or	or	O	CC	O	43	NMOD	O
T24,T25	B-Entity,B-Entity	1439	1441	NF	NF	B-NP	NN	O	43	NMOD	O
T24,T25	I-Entity,I-Entity	1441	1442	-	-	B-NP	HYPH	O	43	NMOD	O
T24,T25	I-Entity,I-Entity	1442	1447	kappa	kappa	I-NP	NN	B-DNA	43	NMOD	B-DNA
T24,T25	I-Entity,I-Entity	1448	1449	B	B	I-NP	NN	I-DNA	43	NMOD	I-DNA
T24	I-Entity	1450	1456	domain	domain	I-NP	NN	I-DNA	31	PMOD	I-DNA
O	O	1456	1457	.	.	O	.	O	7	P	O

O	O	1458	1461	DNA	DNA	B-NP	NN	O	5	NMOD	O
O	O	1462	1466	band	band	I-NP	NN	O	5	NMOD	O
O	O	1466	1467	-	-	B-NP	HYPH	O	5	NMOD	O
O	O	1467	1472	shift	shift	I-NP	NN	O	5	NMOD	O
O	O	1473	1481	analysis	analysis	I-NP	NN	O	6	SUB	O
O	O	1482	1489	reveals	reveal	B-VP	VBZ	O	0	ROOT	O
T26	B-Entity	1490	1492	NF	NF	B-NP	NN	B-protein	12	NMOD	B-protein
T26	I-Entity	1492	1493	-	-	I-NP	HYPH	I-protein	12	NMOD	I-protein
T26	I-Entity	1493	1498	kappa	kappa	I-NP	NN	I-protein	12	NMOD	I-protein
T26	I-Entity	1499	1500	B	B	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	1501	1508	binding	binding	I-NP	NN	O	12	NMOD	O
O	O	1509	1517	activity	activity	I-NP	NN	O	6	OBJ	O
O	O	1518	1520	in	in	B-PP	IN	O	12	NMOD	O
O	O	1521	1526	glial	glial	B-NP	JJ	B-cell_type	15	NMOD	B-cell_type
O	O	1527	1532	cells	cell	I-NP	NNS	I-cell_type	13	PMOD	I-cell_type
O	O	1533	1537	that	that	B-NP	WDT	O	12	NMOD	O
O	O	1538	1545	differs	differ	B-VP	VBZ	O	16	SBAR	O
O	O	1546	1550	from	from	B-PP	IN	O	17	VMOD	O
O	O	1551	1555	that	that	B-NP	DT	O	18	PMOD	O
O	O	1556	1563	present	present	B-ADJP	JJ	O	19	NMOD	O
O	O	1564	1566	in	in	B-PP	IN	O	20	AMOD	O
O	O	1567	1568	T	T	B-NP	NN	B-cell_type	24	NMOD	B-cell_type
O	O	1569	1577	lymphoid	lymphoid	I-NP	JJ	I-cell_type	24	NMOD	I-cell_type
O	O	1578	1583	cells	cell	I-NP	NNS	I-cell_type	21	PMOD	I-cell_type
O	O	1583	1584	.	.	O	.	O	6	P	O

O	O	1585	1592	Further	Further	B-ADVP	RB	O	4	VMOD	O
O	O	1592	1593	,	,	O	,	O	4	P	O
O	O	1594	1596	we	we	B-NP	PRP	O	4	SUB	O
O	O	1597	1604	observe	observe	B-VP	VBP	O	0	ROOT	O
O	O	1605	1609	that	that	B-SBAR	IN	O	4	VMOD	O
T27	B-Entity	1610	1613	TAR	TAR	B-NP	NN	B-DNA	9	NMOD	B-DNA
O	O	1613	1614	-	-	B-NP	HYPH	O	9	NMOD	O
O	O	1614	1621	deleted	delete	I-NP	VBN	O	9	NMOD	O
O	O	1622	1629	mutants	mutant	I-NP	NNS	O	13	NMOD	O
O	O	1630	1632	of	of	B-PP	IN	O	9	NMOD	O
O	O	1633	1636	HIV	HIV	B-NP	NN	O	10	PMOD	O
O	O	1636	1637	-	-	B-NP	HYPH	O	13	P	O
O	O	1637	1638	1	1	I-NP	CD	O	14	SUB	O
O	O	1639	1650	demonstrate	demonstrate	B-VP	VBP	O	5	SBAR	O
O	O	1651	1657	normal	normal	B-NP	JJ	O	18	NMOD	O
T28	B-Entity	1658	1662	late	late	I-NP	JJ	O	18	NMOD	O
T28	I-Entity	1663	1667	gene	gene	I-NP	NN	O	18	NMOD	O
O	O	1668	1678	expression	expression	I-NP	NN	O	14	OBJ	O
O	O	1679	1681	in	in	B-PP	IN	O	18	NMOD	O
O	O	1682	1687	glial	glial	B-NP	JJ	B-cell_type	21	NMOD	B-cell_type
O	O	1688	1693	cells	cell	I-NP	NNS	I-cell_type	19	PMOD	I-cell_type
O	O	1694	1696	as	as	B-SBAR	IN	O	14	VMOD	O
O	O	1697	1706	evidenced	evidence	B-VP	VBN	O	22	SBAR	O
O	O	1707	1709	by	by	B-PP	IN	O	23	VMOD	O
O	O	1710	1718	syncytia	syncytia	B-NP	NN	O	26	NMOD	O
O	O	1719	1728	formation	formation	I-NP	NN	O	28	NMOD	O
O	O	1729	1732	and	and	I-NP	CC	O	28	NMOD	O
O	O	1733	1743	production	production	I-NP	NN	O	24	PMOD	O
O	O	1744	1746	of	of	B-PP	IN	O	28	NMOD	O
O	O	1747	1752	viral	viral	B-NP	JJ	B-protein	32	NMOD	B-protein
T8	B-Protein	1753	1756	p24	p24	I-NP	NN	I-protein	32	NMOD	I-protein
O	O	1757	1764	antigen	antigen	I-NP	NN	I-protein	29	PMOD	I-protein
O	O	1764	1765	.	.	O	.	O	4	P	O

O	O	1766	1767	(	(	O	(	O	7	DEP	O
O	O	1767	1775	ABSTRACT	ABSTRACT	B-NP	NN	O	7	DEP	O
O	O	1776	1785	TRUNCATED	TRUNCATED	B-VP	VBN	O	2	NMOD	O
O	O	1786	1788	AT	AT	B-PP	IN	O	3	VMOD	O
O	O	1789	1792	250	250	B-NP	CD	O	6	NMOD	O
O	O	1793	1798	WORDS	WORDS	I-NP	NNS	O	4	PMOD	O
O	O	1798	1799	)	)	O	)	O	0	ROOT	O
